Post by
PWIB123 on Feb 21, 2024 11:31am
At least another year of waiting...
I love how Paul on the conference call made it sound like a victory of how well the company has crawled out of the deficit of a hole they got themselves into after making financial and operational mistakes. It's hard not to be completely pessimistic. Basically all I took away was that they finally got their spending under control and have flat expectations for the future without something good coming out of oncology. That, and we'll be waiting until the end of 2024 on TH-1902, so still dead money for longer.
Comment by
Trogarzon on Feb 21, 2024 11:53am
Did mention one again strong interest for onco (Novartis is shopping PDCs quote). M&A prority to fill the sales pipeline (Nash stuff maybe). Great support from IQ (I bet considering they paid 12.5M for 20% of teh company compared to something like 200M back in 2018 for the same thing). No mention of BOD changes. More can kicking and wishfull thinking.
Comment by
palinc2000 on Feb 21, 2024 11:56am
He keeps talking about accretive product acquisition for the umpteenth time...Sales are up but not exceeding guidance ,,For sure they are very cautious in everything they say on the advice of theur lawyer..... Hard to be impressed by anything said during the CC....At least the SP does not appear to be overvalued and any bit of good news could have a positive effect
Comment by
Trogarzon on Feb 21, 2024 12:06pm
His tone was downbeat, the conclusion was read blatantly. Not shure why he's being kept onboard. Ok the former CEO was'nt eactly excellent at these calls either but still for a marketing guy it's not exactly filled with enthousiam. Maybe there is none to be communicated.
Comment by
Trogarzon on Feb 21, 2024 5:27pm
This guy should go or be made to go.
Comment by
LouisW on Feb 22, 2024 12:11am
They don't have sufficient cash, I am wondering how do they acquire the new product? The possibility I can image is that TH sale the right of NASH or Th1902 for acquiring the new product.